keyword
MENU ▼
Read by QxMD icon Read
search

Neurorestorative

keyword
https://www.readbyqxmd.com/read/29451447/peripheral-nerve-grafts-implanted-into-the-substantia-nigra-in-patients-with-parkinson-s-disease-during-deep-brain-stimulation-surgery-1-year-follow-up-study-of-safety-feasibility-and-clinical-outcome
#1
Craig G van Horne, Jorge E Quintero, John T Slevin, Amelia Anderson-Mooney, Julie A Gurwell, Andrew S Welleford, John R Lamm, Renee P Wagner, Greg A Gerhardt
OBJECTIVE Currently, there is no treatment that slows or halts the progression of Parkinson's disease. Delivery of various neurotrophic factors to restore dopaminergic function has become a focus of study in an effort to fill this unmet need for patients with Parkinson's disease. Schwann cells provide a readily available source of such factors. This study presents a 12-month evaluation of safety and feasibility, as well as the clinical response, of implanting autologous peripheral nerve grafts into the substantia nigra of patients with Parkinson's disease at the time of deep brain stimulation (DBS) surgery...
February 16, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29408408/combination-of-cdnf-and-deep-brain-stimulation-decreases-neurological-deficits-in-late-stage-model-parkinson-s-disease
#2
Antti Huotarinen, Anna-Maija Penttinen, Susanne Bäck, Merja H Voutilainen, Ulrika Julku, T Petteri Piepponen, Pekka T Männistö, Mart Saarma, Raimo Tuominen, Aki Laakso, Mikko Airavaara
Several neurotrophic factors (NTF) are shown to be neuroprotective and neurorestorative in pre-clinical animal models for Parkinson's disease (PD), particularly in models where striatal dopamine neuron innervation partially exists. The results of clinical trials on late-stage patients have been modest. Subthalamic deep brain stimulation (STN DBS) is a proven treatment for a selected group of advanced PD patients. The cerebral dopamine neurotrophic factor (CDNF) is a promising therapeutic protein, but its effects in animal models of late-stage PD have remained under-researched...
February 3, 2018: Neuroscience
https://www.readbyqxmd.com/read/29386049/an-open-label-proof-of-concept-study-of-intrathecal-autologous-bone-marrow-mononuclear-cell-transplantation-in-intellectual-disability
#3
Alok Sharma, Hemangi Sane, Nandini Gokulchandran, Suhasini Pai, Pooja Kulkarni, Vaishali Ganwir, Maitree Maheshwari, Ridhima Sharma, Meenakshi Raichur, Samson Nivins, Prerna Badhe
BACKGROUND: The underlying pathophysiology in intellectual disability (ID) involves abnormalities in dendritic branching and connectivity of the neuronal network. This limits the ability of the brain to process information. Conceptually, cellular therapy through its neurorestorative and neuroregenerative properties can counteract these pathogenetic mechanisms and improve neuronal connectivity. This improved networking should exhibit as clinical efficacy in patients with ID. METHODS: To assess the safety and efficacy of cellular therapy in patients with ID, we conducted an open-label proof-of-concept study from October 2011 to December 2015...
January 31, 2018: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/29372883/brain-repair-by-hematopoietic-growth-factors-in-the-subacute-phase-of-traumatic-brain-injury
#4
Gentian Toshkezi, Michele Kyle, Sharon L Longo, Lawrence S Chin, Li-Ru Zhao
OBJECTIVE Traumatic brain injury (TBI) is a major cause of long-term disability and death in young adults. The lack of pharmaceutical therapy for post-acute TBI recovery remains a crucial medical challenge. Stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF), which are 2 key hematopoietic growth factors, have shown neuroprotective and neurorestorative effects in experimental stroke. The objective of this study was to determine the therapeutic efficacy of combined treatment (SCF + G-CSF) in subacute TBI...
January 26, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29343699/collagen-binding-hepatocyte-growth-factor-hgf-alone-or-with-a-gelatin-furfurylamine-hydrogel-enhances-functional-recovery-in-mice-after-spinal-cord-injury
#5
Kentaro Yamane, Tetsuro Mazaki, Yasuyuki Shiozaki, Aki Yoshida, Kensuke Shinohara, Mariko Nakamura, Yasuhiro Yoshida, Di Zhou, Takashi Kitajima, Masato Tanaka, Yoshihiro Ito, Toshifumi Ozaki, Akihiro Matsukawa
The treatment of spinal cord injury (SCI) is currently a significant challenge. Hepatocyte growth factor (HGF) is a multipotent neurotrophic and neuroregenerative factor that can be beneficial for the treatment of SCI. However, immobilized HGF targeted to extracellular matrix may be more effective than diffusible, unmodified HGF. In this study, we evaluated the neurorestorative effects of an engineered HGF with a collagen biding domain (CBD-HGF). CBD-HGF remained in the spinal cord for 7 days after a single administration, while unmodified HGF was barely seen at 1 day...
January 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29332089/gene-therapy-for-parkinson-s-disease
#6
Vivek Sudhakar, R Mark Richardson
Gene therapy is a clinical tool that may eventually provide therapeutic benefit to patients suffering from movement disorders through a few potential mechanisms: direct correction of the pathogenic mechanism, neuroprotection, neurorestoration or symptom control. The therapeutic mechanism is therefore dependent on knowledge of disease pathogenesis and the required temporal and spatial specificities of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces...
2018: Progress in Neurological Surgery
https://www.readbyqxmd.com/read/29304004/effects-of-fluoxetine-on-hippocampal-neurogenesis-and-neuroprotection-in-the-model-of-global-cerebral-ischemia-in-rats
#7
Marina Khodanovich, Alena Kisel, Marina Kudabaeva, Galina Chernysheva, Vera Smolyakova, Elena Krutenkova, Irina Wasserlauf, Mark Plotnikov, Vasily Yarnykh
A selective serotonin reuptake inhibitor, fluoxetine, has recently attracted a significant interest as a neuroprotective therapeutic agent. There is substantial evidence of improved neurogenesis under fluoxetine treatment of brain ischemia in animal stroke models. We studied long-term effects of fluoxetine treatment on hippocampal neurogenesis, neuronal loss, inflammation, and functional recovery in a new model of global cerebral ischemia (GCI). Brain ischemia was induced in adult Wistar male rats by transient occlusion of three main vessels originating from the aortic arch and providing brain blood supply...
January 5, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29288070/neonatal-erythropoietin-mitigates-impaired-gait-social-interaction-and-diffusion-tensor-imaging-abnormalities-in-a-rat-model-of-prenatal-brain-injury
#8
Shenandoah Robinson, Christopher J Corbett, Jesse L Winer, Lindsay A S Chan, Jessie R Maxwell, Christopher V Anstine, Tracylyn R Yellowhair, Nicholas A Andrews, Yirong Yang, Laurel O Sillerud, Lauren L Jantzie
Children who are born preterm are at risk for encephalopathy of prematurity, a leading cause of cerebral palsy, cognitive delay and behavioral disorders. Current interventions are limited and none have been shown to reverse cognitive and behavioral impairments, a primary determinant of poor quality of life for these children. Moreover, the mechanisms of perinatal brain injury that result in functional deficits and imaging abnormalities in the mature brain are poorly defined, limiting the potential to target interventions to those who may benefit most...
December 26, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/29170452/liraglutide-restores-chronic-er-stress-autophagy-impairments-and-apoptotic-signalling-in-sh-sy5y-cells
#9
Theodora Panagaki, Maria Michael, Christian Hölscher
Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert neuroprotective and neurorestorative effects across a range of experimental models of neuronal degeneration, and, recently, a pilot clinical trial of Liraglutide in Alzheimer's disease patients showed improvements in cerebral glucose consumption that signifies disease progression. However, the exact underlying mechanism of action remains unclear. Chronic endoplasmic reticulum (ER) stress has recently emerged as a mechanism for neuronal injury, rendering it a potent therapeutic target for acute and chronic neurodegenerative disorders...
November 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29163139/exercise-induced-neuroprotection-of-the-nigrostriatal-dopamine-system-in-parkinson-s-disease
#10
REVIEW
Lijuan Hou, Wei Chen, Xiaoli Liu, Decai Qiao, Fu-Ming Zhou
Epidemiological studies indicate that physical activity and exercise may reduce the risk of developing Parkinson's disease (PD), and clinical observations suggest that physical exercise can reduce the motor symptoms in PD patients. In experimental animals, a profound observation is that exercise of appropriate timing, duration, and intensity can reduce toxin-induced lesion of the nigrostriatal dopamine (DA) system in animal PD models, although negative results have also been reported, potentially due to inappropriate timing and intensity of the exercise regimen...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29132545/nanoformulation-a-useful-therapeutic-strategy-for-improving-neuroprotection-and-the-neurorestorative-potential-in-experimental-models-of-parkinson-s-disease
#11
Jose V Lafuente, Catalina Requejo, Alejandro Carrasco, Harkaitz Bengoetxea
Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, but current therapies are only symptomatic. Experimental models are necessary to go deeper in the comprehension of pathophysiological mechanism and to assess new therapeutic strategies. The unilateral 6-hydroxydopamine (6-OHDA) lesion either in medial forebrain bundle (MFB) or into the striatum in rats affords to study various stages of PD depending on the evolution time lapsed. A promising alternative to address the neurodegenerative process is the use of neurotrophic factors; but its clinical use has been limited due to its short half-life and rapid degradation after in vivo administration, along with difficulties for crossing the blood-brain barrier (BBB)...
2017: International Review of Neurobiology
https://www.readbyqxmd.com/read/29113472/cell-therapy-for-parkinson-s-disease
#12
Takao Yasuhara, Masahiro Kameda, Tatsuya Sasaki, Naoki Tajiri, Isao Date
Cell therapy for Parkinson's disease (PD) began in 1979 with the transplantation of fetal rat dopamine-containing neurons that improved motor abnormalities in the PD rat model with good survival of grafts and axonal outgrowth. Thirty years have passed since the 2 clinical trials using cell transplantation for PD patients were first reported. Recently, cell therapy is expected to develop as a realistic treatment option for PD patients owing to the advancement of biotechnology represented by pluripotent stem cells...
September 2017: Cell Transplantation
https://www.readbyqxmd.com/read/29100803/the-effects-of-cysteamine-in-a-mouse-model-of-levodopa-induced-dyskinesias
#13
Linda S David, Martine Saint-Pierre, Jérôme Lamontagne-Proulx, Francesca Cicchetti
Levo-dopa (L-DOPA) has shown significant and long-lasting efficacy in the treatment of motor features characteristic of Parkinson's disease (PD). However, the effects tend to wear off at a time typically when side-effects, such as L-DOPA induced dyskinesias (LIDs), start to emerge and for which the treatment options are very limited. In recent years, we have reported on the neuroprotective and neurorestorative properties of the compounds cystamine/cysteamine in ameliorating several aspects of PD. Building on these observations, we set out to further evaluate the benefits of cysteamine on LIDs...
October 31, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/29094222/restorative-strategies-in-movement-disorders-the-contribution-of-imaging
#14
REVIEW
Nicholas P Lao-Kaim, Paola Piccini, Yen F Tai
PURPOSE OF REVIEW: The purpose of this review was to review the imaging, particularly positron emission tomography (PET), findings in neurorestoration studies in movement disorders, with specific focus on neural transplantation in Parkinson's disease (PD) and Huntington's disease (HD). RECENT FINDINGS: PET findings in PD transplantation studies have shown that graft survival as reflected by increases in dopaminergic PET markers does not necessarily correlate with clinical improvement...
November 2, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/29053638/neuroprotective-surgical-strategies-in-parkinson-s-disease-role-of-preclinical-data
#15
REVIEW
Napoleon Torres, Jenny Molet, Cecile Moro, John Mitrofanis, Alim Louis Benabid
Although there have been many pharmacological agents considered to be neuroprotective therapy in Parkinson's disease (PD) patients, neurosurgical approaches aimed to neuroprotect or restore the degenerative nigrostriatal system have rarely been the focus of in depth reviews. Here, we explore the neuroprotective strategies involving invasive surgical approaches (NSI) using neurotoxic models 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), which have led to clinical trials. We focus on several NSI approaches, namely deep brain stimulation of the subthalamic nucleus, glial neurotrophic derived factor (GDNF) administration and cell grafting methods...
October 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29017388/pathophysiological-bases-of-comorbidity-traumatic-brain-injury-and-post-traumatic-stress-disorder
#16
Gary B Kaplan, Kimberly A Leite-Morris, Lei Wang, Kendra K Rumbika, Stephen C Heinrichs, Xiang Zeng, Liquan Wu, Danielle T Arena, Yang D Teng
The high rates of traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) diagnoses encountered in recent years by the United States Veterans Affairs Healthcare System have increased public awareness and research investigation into these conditions. In this review, we analyze the neural mechanisms underlying the TBI/PTSD comorbidity. TBI and PTSD present with common neuropsychiatric symptoms including anxiety, irritability, insomnia, personality changes, and memory problems, and this overlap complicates diagnostic differentiation...
January 15, 2018: Journal of Neurotrauma
https://www.readbyqxmd.com/read/28988910/neuroprotection-and-neurorestoration-as-experimental-therapeutics-for-parkinson-s-disease
#17
REVIEW
Veronica Francardo, Yvonne Schmitz, David Sulzer, M Angela Cenci
Disease-modifying treatments remain an unmet medical need in Parkinson's disease (PD). Such treatments can be operationally defined as interventions that slow down the clinical evolution to advanced disease milestones. A treatment may achieve this outcome by either inhibiting primary neurodegenerative events ("neuroprotection") or boosting compensatory and regenerative mechanisms in the brain ("neurorestoration"). Here we review experimental paradigms that are currently used to assess the neuroprotective and neurorestorative potential of candidate treatments in animal models of PD...
October 5, 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28967098/epigenetic-regulation-of-melatonin-receptors-in-neuropsychiatric-disorders
#18
REVIEW
Sarra G Bahna, Lennard P Niles
Melatonin, the primary indoleamine hormone of the mammalian pineal gland, is known to have a plethora of neuroregulatory, neuroprotective and other properties. Melatonergic signaling is mediated by its two G protein-coupled receptors, MT1 and MT2 , which are widely expressed in the mammalian CNS. Melatonin levels and receptor expression often show a decrease during normal aging, and this reduction may be accelerated in some disease states. Depleted melatonergic signaling has been associated with neuropsychiatric dysfunction and impairments in cognition, memory, neurogenesis and neurorestorative processes...
October 2, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28923278/can-adjunctive-therapies-augment-the-efficacy-of-endovascular-thrombolysis-a-potential-role-for-activated-protein-c
#19
REVIEW
Arun Paul Amar, Abhay P Sagare, Zhen Zhao, Yaoming Wang, Amy R Nelson, John H Griffin, Berislav V Zlokovic
In the management of acute ischemic stroke, vessel recanalization correlates with functional status, mortality, cost, and other outcome measures. Thrombolysis with intravenous tissue plasminogen activator has many limitations that restrict its applicability, but recent advances in the development of mechanical thrombectomy devices as well as improved systems of stroke care have resulted in greater likelihood of vessel revascularization. Nonetheless, there remains substantial discrepancy between rates of recanalization and rates of favorable outcome...
September 18, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28867364/cell-based-and-pharmacological-neurorestorative-therapies-for-ischemic-stroke
#20
REVIEW
Poornima Venkat, Yi Shen, Michael Chopp, Jieli Chen
Ischemic stroke remains one of most common causes of death and disability worldwide. Stroke triggers a cascade of events leading to rapid neuronal damage and death. Neuroprotective agents that showed promise in preclinical experiments have failed to translate to the clinic. Even after decades of research, tPA remains the only FDA approved drug for stroke treatment. However, tPA is effective when administered 3-4.5 h after stroke onset and the vast majority of stroke patients do not receive tPA therapy. Therefore, there is a pressing need for novel therapies for ischemic stroke...
September 1, 2017: Neuropharmacology
keyword
keyword
12290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"